Status:
RECRUITING
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Arthritis
Polymyalgia Rheumatica
Eligibility:
All Genders
18+ years
Brief Summary
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Detailed Description
1. To understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impa...
Eligibility Criteria
Inclusion Criteria
The criteria are:
- Patients aged 18 years and above
- English (conversational level) speaking, with the ability to give informed consent
- Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy
Exclusion Criteria
- Acutely life-threatening or worsening cancer
- Hearing impairment functionally limiting participation in verbal interview
Key Trial Info
Start Date :
September 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06647134
Start Date
September 11 2024
End Date
March 31 2028
Last Update
April 13 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030